BiotechTube

AK129 + AK117

Phase 1/2Recruiting
0 watching 0 views this week⚡ Active
40
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Classic Hodgkin Lymphoma

Conditions

Classic Hodgkin Lymphoma

Trial Timeline

Jan 17, 2025 → Feb 1, 2028

NCT ID
NCT06642792

About AK129 + AK117

AK129 + AK117 is a phase 1/2 stage product being developed by Akeso for Classic Hodgkin Lymphoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06642792. Target conditions include Classic Hodgkin Lymphoma.

Hype Score Breakdown

Clinical
13
Activity
8
Company
9
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT06642792Phase 1/2Recruiting

Competing Products

15 competing products in Classic Hodgkin Lymphoma

See all competitors
ProductCompanyStageHype Score
Camrelizumab + Investigator's choice of ChemotherapyJiangsu Hengrui MedicinePhase 3
77
Sabestomig (AZD7789)AstraZenecaPhase 1
33
THOR-707 + PembrolizumabMerckPhase 2
52
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Brentuximab vedotinMerckPhase 2
52
Pembrolizumab + Doxorubicin + Vinblastine + Dacarbazine + Bleomycin + Etoposide + Cyclophosphamide + Vincristine + Procarbazine + PrednisoneMerckPhase 2
52
Dacarbazine + Doxorubicin Hydrochloride + Pembrolizumab + Vinblastine SulfateMerckPhase 2
52
Carboplatin + Etoposide + Ifosfamide + PembrolizumabMerckPhase 2
52
Pembrolizumab (+) Berahyaluronidase alfaMerckPhase 2
52
PanobinostatNovartisPhase 2
52
PD1Innovent BiologicsPhase 2
51
Sintilimab + Carboplatin + Etoposide + Ifosfamide + Placebo + Carboplatin + Etoposide + IfosfamideInnovent BiologicsPhase 3
76
Nivolumab + Autologous CD30.CAR-T + Fludarabine + BendamustineBristol Myers SquibbPhase 1
32
Nivolumab + IpilimumabBristol Myers SquibbPhase 2
51
Tislelizumab + Salvage ChemotherapyBeOne MedicinesPhase 3
74
GEN3017GenmabPhase 1/2
38

Other Products from Akeso

AK104(SC) + AK104(IV) + Capecitabine + Oxaliplatin injectionPhase 3
76
AK111 + AK111 + PlaceboPhase 3
76
AK104 + LenvatinibPhase 3
76
Cadonilimab (AK104) + Oxaliplatin + Capecitabine + 5- Fluorouracil + Calcium FolinatePhase 3
76
AK102 + AK102 + Placebo + PlaceboPhase 3
76